MENU
+Compare
MLYS
Stock ticker: NASDAQ
AS OF
Jun 5, 04:59 PM (EDT)
Price
$15.61
Change
+$0.09 (+0.58%)
Capitalization
1.01B

MLYS Mineralys Therapeutics Forecast, Technical & Fundamental Analysis

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone... Show more

MLYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for MLYS with price predictions
Jun 04, 2025

MLYS in +3.85% Uptrend, advancing for three consecutive days on June 03, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MLYS advanced for three days, in of 119 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Aroon Indicator entered an Uptrend today. In of 67 cases where MLYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for MLYS moved out of overbought territory on May 23, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator moved out of overbought territory. In of the 13 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 23 cases where MLYS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on June 04, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MLYS as a result. In of 35 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MLYS turned negative on May 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 24 similar instances when the indicator turned negative. In of the 24 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLYS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MLYS broke above its upper Bollinger Band on May 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.961) is normal, around the industry mean (16.306). P/E Ratio (0.000) is within average values for comparable stocks, (59.921). MLYS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (265.014).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MLYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLYS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
MLYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

MLYS is expected to report earnings to rise 34.18% to -105 cents per share on August 11

Mineralys Therapeutics MLYS Stock Earnings Reports
Q2'25
Est.
$-1.06
Q1'25
Beat
by $0.29
Q4'24
Missed
by $0.27
Q3'24
Missed
by $0.42
Q2'24
Missed
by $0.11
The last earnings report on May 12 showed earnings per share of -79 cents, beating the estimate of -108 cents. With 147.32K shares outstanding, the current market capitalization sits at 1.01B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
150 North Radnor Chester Road
Phone
+1 888 378-6240
Employees
28
Web
https://mineralystx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IJEMX14.22N/A
N/A
VY® JPMorgan Emerging Markets Equity I
ODVIX40.73N/A
N/A
Invesco Developing Markets R6
HFYRX11.98N/A
N/A
Hartford Schroders Intl Multi-Cp Val R3
AVUSX18.61N/A
N/A
Avantis® U.S. Equity Institutional
BTEEX13.91N/A
N/A
Baron Technology Retail

MLYS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with PTGX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLYS
1D Price
Change %
MLYS100%
-4.08%
PTGX - MLYS
49%
Loosely correlated
+0.92%
XERS - MLYS
37%
Loosely correlated
-4.73%
ACLX - MLYS
36%
Loosely correlated
+0.52%
APGE - MLYS
35%
Loosely correlated
-1.56%
CRNX - MLYS
35%
Loosely correlated
+0.78%
More